Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/32095
Tipo
ArtículoDerechos de autor
Acceso restringido
Fecha del embargo
2022-01-01
Colecciones
- IOC - Artigos de Periódicos [12678]
Metadatos
Mostrar el registro completo del ítem
INTEGRIN D 2 IS DYNAMICALLY EXPRESSED BY INFLAMED MACROPHAGES AND ALTERS THE NATURAL HISTORY OF LETHAL SYSTEMIC INFECTIONS
Macrófagos inflamados
Infecções Sistêmicas letais
Alterações
Autor
Afiliación
University of Utah. Program in Human Molecular Biology and Genetics.Salt Lake City, UT, USA.
University of Utah. Program in Human Molecular Biology and Genetics.Salt Lake City, UT, USA.
University of Utah. Huntsman Cancer Institute. Salt Lake City, UT, USA / University of Utah. Department of Internal Medicine. Salt Lake City, UT, USA.
University of Utah. Program in Human Molecular Biology and Genetics.Salt Lake City, UT, USA /University of Utah. Department of Internal Medicine. Salt Lake City, UT, USA.
University of Utah. Department of Internal Medicine. Salt Lake City, UT, USA / University of Utah. Department of Pathology. Salt Lake City, UT, USA.
University of Utah. Huntsman Cancer Institute. Salt Lake City, UT, USA / University of Utah. Department of Internal Medicine. Salt Lake City, UT, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Fisiologia e Farmacodinâmica. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Fisiologia e Farmacodinâmica. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Fisiologia e Farmacodinâmica. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Fisiologia e Farmacodinâmica. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
University of Utah. Program in Human Molecular Biology and Genetics.Salt Lake City, UT, USA /University of Utah. Department of Internal Medicine. Salt Lake City, UT, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Fisiologia e Farmacodinâmica. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
University of Utah. Program in Human Molecular Biology and Genetics.Salt Lake City, UT, USA /University of Utah. Department of Internal Medicine. Salt Lake City, UT, USA.
University of Utah. Program in Human Molecular Biology and Genetics.Salt Lake City, UT, USA.
University of Utah. Huntsman Cancer Institute. Salt Lake City, UT, USA / University of Utah. Department of Internal Medicine. Salt Lake City, UT, USA.
University of Utah. Program in Human Molecular Biology and Genetics.Salt Lake City, UT, USA /University of Utah. Department of Internal Medicine. Salt Lake City, UT, USA.
University of Utah. Department of Internal Medicine. Salt Lake City, UT, USA / University of Utah. Department of Pathology. Salt Lake City, UT, USA.
University of Utah. Huntsman Cancer Institute. Salt Lake City, UT, USA / University of Utah. Department of Internal Medicine. Salt Lake City, UT, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Fisiologia e Farmacodinâmica. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Fisiologia e Farmacodinâmica. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Fisiologia e Farmacodinâmica. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Fisiologia e Farmacodinâmica. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
University of Utah. Program in Human Molecular Biology and Genetics.Salt Lake City, UT, USA /University of Utah. Department of Internal Medicine. Salt Lake City, UT, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Fisiologia e Farmacodinâmica. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
University of Utah. Program in Human Molecular Biology and Genetics.Salt Lake City, UT, USA /University of Utah. Department of Internal Medicine. Salt Lake City, UT, USA.
Resumen en ingles
The leukocyte integrins have critical roles in host defense and inflammatory tissue injury. We found that integrin D 2, a novel but
largely uncharacterized member of this family, is restricted to subsets of macrophages and a small population of circulating leukocytes
in wild-type mice in the absence of inflammatory challenge and is expressed in regulated fashion during cytokine-induced macrophage
differentiation in vitro. D 2 is highly displayed on splenic red pulp macrophages and mediates their adhesion to local targets, identifying
key functional activity. In response to challenge with Plasmodium berghei, a malarial pathogen that models systemic infection and
inflammatory injury, new populations of D
macrophages evolved in the spleen and liver. Unexpectedly, targeted deletion of D
conferred a survival advantage in P. berghei infection over a 30-day observation period. Mechanistic studies demonstrated that the
increased survival of D
/ animals at these time points is not attributed to differences in magnitude of anemia or parasitemia or to
alterations in splenic microanatomy, each of which is a key variable in the natural history of P. berghei infection, and indicated that an
altered pattern of inflammatory cytokines may contribute to the difference in mortality. In contrast to the outcome in malarial challenge,
death of D
/ animals was accelerated in a model of Salmonella sepsis, demonstrating differential rather than stereotyped roles for
D 2 in systemic infection. These studies identify previously unrecognized and unique activities of D 2, and macrophages that express
it, in host defense and injury.
Palabras clave en portugues
ntegrin D 2Macrófagos inflamados
Infecções Sistêmicas letais
Alterações
Compartir